Dujovne 2000.

Methods	6‐8‐week run‐in phase 8‐week before‐and‐after study
Participants	479 men and women with type IIa or IIb hypercholesterolaemia age 18‐75 years old TG < 350 mg/dL (3.95 mmol/L) Exclusion criteria: history of MI, angina, stroke, recent TIA, recent coronary revascularisation, uncontrolled hypertension or hypothyroidism, type 2 diabetes, chronic liver disease, renal dysfunction, alcohol or drug abuse, CPK values are 3 x ULN Cerivastatin 0.3 mg/d baseline TC: 6.7 mmol/L (259 mg/dL) Cerivastatin 0.3 mg/d baseline LDL‐C: 4.49 mmol/L (174 mg/dL) Cerivastatin 0.3 mg/d baseline HDL‐C: 1.3 mmol/L (50 mg/dL) Cerivastatin 0.3 mg/d baseline TG: 1.99 mmol/L (176 mg/dL) Cerivastatin 0.4 mg/d baseline TC: 6.75 mmol/L (261 mg/dL) Cerivastatin 0.4 mg/d baseline LDL‐C: 4.55 mmol/L (176 mg/dL) Cerivastatin 0.4 mg/d baseline HDL‐C: 1.3 mmol/L (50 mg/dL) Cerivastatin 0.4 mg/d baseline TG: 1.98 mmol/L (175 mg/dL)
Interventions	Cerivastatin 0.3 mg/d evening dosing Cerivastatin 0.4 mg/d evening dosing Pravastatin 20 mg/d evening dosing Pravastatin 40 mg/d evening dosing
Outcomes	Percentage change from baseline at 8 weeks of serum TC, LDL‐C, HDL‐C and TG
Source of funding	Bayer
Notes	Pravastatin 20 mg/d and pravastatin 40 mg/d groups were not analysed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before‐and‐after design
Allocation concealment (selection bias)	High risk	Controlled before‐and‐after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐C	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAE	High risk	No comparison possible
Incomplete outcome data (attrition bias) Total cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) LDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) HDL cholesterol	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias) Triglycerides	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	High risk	Bayer funded the trial, data may support bias for cerivastatin